# EDGAR Filing Document

**Accession Number:** 0000818686
**File Stem:** 0001171843-26-000174
**Filing Date:** 2026-1
**Character Count:** 15687
**Document Hash:** 6c3d716ce691d7e06ca4f4903dc63672
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-000174.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001171843-26-000174

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260111

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TEVA PHARMACEUTICAL INDUSTRIES LTD
- **CENTRAL INDEX KEY:** 0000818686
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-16174
- **FILM NUMBER:** 26524520

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- **STREET 2:** 124 DVORA HANEVI'A ST.
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972 (3) 914-8213

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- **STREET 2:** 124 DVORA HANEVI'A ST.
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3

?xml version='1.0' encoding='ASCII'? Form 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549
_________________

### FORM 8-K
_________________

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 11, 2026
_______________________________

#### TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)

_______________________________

---

| | | |
|:---|:---|:---|
| **Israel** | **001-16174** | **Not Applicable** |
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |

---

#### 124 Dvora Hanevi'a Street

#### Tel Aviv 6944020, Israel
(Address of Principal Executive Offices, including Zip Code)

#### +972-3-914-8213
(Registrant's Telephone Number, including Area Code)

#### Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| American Depositary Shares, each representing one Ordinary Share | TEVA | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On January 11, 2026, Teva Pharmaceutical Industries Ltd. (the "Company") issued a press release (the "Press Release") in connection with the Company's presentation on Tuesday, January 13, 2026 at the 44th Annual J.P. Morgan Healthcare Conference. The Press Release includes the Company's expectations regarding its performance for the 2025 fiscal year. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.

The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description of Document</u>** |
| [99.1](exh_991.htm) | [Teva to Present at the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivers Growth and Transforms through Innovation](exh_991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TEVA PHARMACEUTICAL INDUSTRIES LIMITED** | **TEVA PHARMACEUTICAL INDUSTRIES LIMITED** |
| Date: January 11, 2026 | By: | <u>/s/ Eli Kalif&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Eli Kalif |
|  |  | Executive Vice President, Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation**

Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)

TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference. Teva's President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company's milestones achieved in 2025, transformative initiatives, and forward-looking outlook for 2026 and beyond.

**Presentation Highlights:**

* **Pivot to Growth Strategy Progress**: Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical company through late-stage innovative pipeline, fueled by its world-class generics business.

* **Innovation at the Heart of Teva's Transformation**: Teva's key innovative brands – AUSTEDO<sup>®</sup>, AJOVY<sup>®</sup> and UZEDY<sup>®</sup> – are already driving its growth and reshaping Teva's financial outlook. Teva's clinical pipeline assets – olanzapine LAI, DARI (ICS/SABA), duvakitug (anti-TL1A), emrusolmin, and anti-IL-15 – are expected to drive Teva's long-term growth trajectory and further Teva's transformation.

* **2025 Performance**: Teva to provide its expected 2025 financial performance.

* **2026 and Beyond**: In addition, Teva to provide forward-looking outlook for 2026 and beyond, underlining disciplined capital allocation and a commitment to securing an investment-grade credit rating.

**Expected 2025 Performance** 

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp; **$ billions, except EPS or as noted** | **2025 Outlook** | **Expected 2025 performance relative to Outlook (excluding duvakitug milestones)** | **Additional contribution from expected duvakitug milestones** |
| &nbsp;&nbsp; Revenues\* | &nbsp;&nbsp;&nbsp;&nbsp; $16.8 - $17.0 | Lower point of the range | $500M |
| &nbsp;&nbsp; Operating Margin | &nbsp;&nbsp;&nbsp;&nbsp; ~26.2% - 27.1% | Mid to high point of the range | ~80%-85% |
| &nbsp;&nbsp; Adjusted EBITDA | &nbsp;&nbsp;&nbsp;&nbsp; $4.8 - $5.0 | Midpoint of the range | ~$400M-$430M |
| &nbsp;&nbsp; Tax Rate | &nbsp;&nbsp;&nbsp;&nbsp; 15%-18% | Lower point of the range |  |
| &nbsp;&nbsp; Diluted EPS ($) | &nbsp;&nbsp;&nbsp;&nbsp; 2.55 - 2.65 | Higher point of the range |  |
| &nbsp;&nbsp; Free Cash Flow\*\* | &nbsp;&nbsp;&nbsp;&nbsp; $1.6 - $1.9 | Higher point of the range | ~$500M |
| &nbsp;&nbsp; Net leverage | &nbsp;&nbsp;&nbsp;&nbsp; ~2.5x - 2.9x | Midpoint of the range | ~2.5x |

---

 **Path to achieving 2027 targets and additional 2030 targets**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp; **$billionsor as noted** | **2026** | **2027** | **2030** |
| &nbsp;&nbsp; Revenues\* | &nbsp;&nbsp;&nbsp;&nbsp; Flat to slightly down vs. 2025 | &nbsp;&nbsp;&nbsp;&nbsp; Low-single digit growth | Mid-single digit CAGR |
| &nbsp;&nbsp; Operating Profit | &nbsp;&nbsp;&nbsp;&nbsp; Growing vs. 2025 | &nbsp;&nbsp;&nbsp;&nbsp; 30% | >30% |
| &nbsp;&nbsp; Adjusted EBITDA | &nbsp;&nbsp;&nbsp;&nbsp; Growing vs. 2025 | &nbsp;&nbsp;&nbsp;&nbsp; Growing vs. 2026 | Growing |
| &nbsp;&nbsp; Free Cash Flow\*\* | &nbsp;&nbsp;&nbsp;&nbsp; Growing vs. 2025 | &nbsp;&nbsp;&nbsp;&nbsp; >$2.7 | >$3.5 |
| &nbsp;&nbsp; Net Leverage | &nbsp;&nbsp;&nbsp;&nbsp; ~2.0-2.2x | &nbsp;&nbsp;&nbsp;&nbsp; <2x | <2x |
| &nbsp;&nbsp; Cumulative Transformation Programs Savings | &nbsp;&nbsp;&nbsp;&nbsp; ~$450M-500M | &nbsp;&nbsp;&nbsp;&nbsp; ~$700M |  |

---

<sup>Note: 2026 commentary compared to 2025 results *excluding duvakitug milestones, except for net debt leverage calculation*.</sup> 

<sup>\* Revenues presented on a GAAP basis; all other metrics presented on a non-GAAP basis.</sup> 

<sup>\*\* Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.</sup>

To access a live webcast of the presentation, visit Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.

An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.

**About Teva**

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to better health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

**Non-GAAP Financial Measures** 

This press release includes certain non-GAAP financial measures as defined by SEC rules. Management believes that such non-GAAP financial measures provide useful information to investors to facilitate their understanding of our business because the non-GAAP financial measures are used by Teva's management and board of directors, in conjunction with other performance metrics, to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management; the company's annual budgets are prepared on a non-GAAP basis; and senior management's annual compensation is derived, in part, using these non-GAAP measures. Investors should consider the non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. In the case of the non-GAAP financial measures disclosed in this press release, we are not providing comparable forward looking guidance for GAAP financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.

**Teva Cautionary Note Regarding Forward Looking Statements**

This Press Release and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "outlook" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors" and "Forward-looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com <br> Teva Investor Relations Inquiries TevaIR@Tevapharm.com